Article Versions Notes

Kirsten N, Ohm F, Gehrdau K, Girbig G, Stephan B, Ben-Anaya N, Pinter A, Bechara FG, Presser D, Zouboulis CC, et al. Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest. Life. 2022; 12(10):1518. https://doi.org/10.3390/life12101518

Kirsten, Natalia, Frenz Ohm, Kathrin Gehrdau, Gefion Girbig, Brigitte Stephan, Nesrine Ben-Anaya, Andreas Pinter, Falk G. Bechara, Dagmar Presser, Christos C. Zouboulis, and et al. 2022. "Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest" Life 12, no. 10: 1518. https://doi.org/10.3390/life12101518

Kirsten, N., Ohm, F., Gehrdau, K., Girbig, G., Stephan, B., Ben-Anaya, N., Pinter, A., Bechara, F. G., Presser, D., Zouboulis, C. C., & Augustin, M. (2022). Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest. Life, 12(10), 1518. https://doi.org/10.3390/life12101518